Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus

By sjmartinez • November 30, 2023

Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Oct 31;14:1242830. doi: 10.3389/fendo.2023.1242830. PMID: 38027216; PMCID: PMC10643762.

Tags: autoimmune endocrinopathy, Endocrinology, General Internal Medicine, Hematology/Oncology, immune checkpoint inhibitor, immune related adverse events, Olive View DoM, Publications, safety, type 1 diabetes mellitus

Related Posts

DDX20 is required for cell-cycle reentry of prospermatogonia and establishment of spermatogonial stem cell pool during testicular development in mice

Zou D, Li K, Su L, Liu J, Lu Y, Huang R, Li M, Mang X, Geng Q, Li P, Tang J, Yu Z, Zhang[...]

Author Correction: Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia

Koeberl D, Schulze A, Sondheimer N, Lipshutz GS, Geberhiwot T, Li L, Saini R, Luo J, Sikirica V, Jin L, Liang M, Leuchars M, Grunewald[...]

Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People With Type 2 Diabetes

Kwak SH, Hernandez-Cancela RB, DiCorpo DA, Condon DE, Merino J, Wu P, Brody JA, Yao J, Guo X, Ahmadizar F, Meyer M, Sincan M, Mercader[...]